Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy.
Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy.
复制标题
DOI：
10.3389/fcell.2021.686453
复制
发表时间：
2021
影响因子：
5.5
通讯作者：
Jarahian M
中科院分区：
文献类型：
--
作者：
Hassanzadeh A;Altajer AH;Rahman HS;Saleh MM;Bokov DO;Abdelbasset WK;Marofi F;Zamani M;Yaghoubi Y;Yazdanifar M;Pathak Y;Chartrand MS;Jarahian M
间充质干/基质细胞（MSC）为基础的治疗已成为一个有吸引力的和先进的科学研究领域的背景下，癌症治疗。这种兴趣与MSC标记的肿瘤向性密切相关，表明它们是血液学和实体恶性肿瘤药物递送的合理有效的载体。尽管如此，MSC在人类肿瘤中的治疗应用仍然是有争议的，因为诱导的几个信号通路在很大程度上有助于肿瘤的进展和转移。尽管有证据表明骨髓间充质干细胞可能参与肿瘤的发生，但越来越多的证据表明骨髓间充质干细胞对肿瘤细胞具有抑制作用。在过去的几年中，已经进行或正在进行大量的临床前和一些临床研究，以解决基于MSC的治疗剂递送在不同类型的恶性肿瘤中的安全性和有效性。大量研究集中在MSC作为肿瘤坏死因子相关凋亡诱导配体（TRAIL）、化疗药物如吉西他滨（GCB）、紫杉醇（PTX）和阿霉素（DOX）、前药如5-氟胞嘧啶（5-FC）和更昔洛韦（GCV）以及免疫细胞活化细胞因子沿着溶瘤病毒的递送载体的应用。在目前的审查中，我们评估了最新的研究结果，使潜在的骨髓间充质干细胞被用作有效的基因/药物递送载体诱导肿瘤消退，特别关注在过去二十年中进行的体内报告。
Mesenchymal stem/stromal cell (MSC)-based therapy has become an attractive and advanced scientific research area in the context of cancer therapy. This interest is closely linked to the MSC-marked tropism for tumors, suggesting them as a rational and effective vehicle for drug delivery for both hematological and solid malignancies. Nonetheless, the therapeutic application of the MSCs in human tumors is still controversial because of the induction of several signaling pathways largely contributing to tumor progression and metastasis. In spite of some evidence supporting that MSCs may sustain cancer pathogenesis, increasing proofs have indicated the suppressive influences of MSCs on tumor cells. During the last years, a myriad of preclinical and some clinical studies have been carried out or are ongoing to address the safety and efficacy of the MSC-based delivery of therapeutic agents in diverse types of malignancies. A large number of studies have focused on the MSC application as delivery vehicles for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), chemotherapeutic drug such as gemcitabine (GCB), paclitaxel (PTX), and doxorubicin (DOX), prodrugs such as 5-fluorocytosine (5-FC) and ganciclovir (GCV), and immune cell-activating cytokines along with oncolytic virus. In the current review, we evaluate the latest findings rendering the potential of MSCs to be employed as potent gene/drug delivery vehicle for inducing tumor regression with a special focus on the in vivo reports performed during the last two decades.
登录
查看更多内容
影响因子：
12.4
作者：
Chen, Xiancheng;Lin, Xiaojuan;Zhao, Xia
通讯作者：
Zhao, Xia
影响因子：
3
作者：
Cocce, Valentina;Bonomi, Arianna;Pessina, Augusto
通讯作者：
Pessina, Augusto
DOI：
10.1080/21691401.2018.1434185
发表时间：
2018-01-01
影响因子：
5.8
作者：
Cao, Shunxiu;Guo, Jiamin;Jin, Liang
通讯作者：
Jin, Liang
影响因子：
12.4
作者：
Ahmed, Atique U.;Rolle, Cleo E.;Lesniak, Maciej S.
通讯作者：
Lesniak, Maciej S.
影响因子：
4.5
作者：
Bonomi, Arianna;Sordi, Valeria;Pessina, Augusto
通讯作者：
Pessina, Augusto